FDA seeks more time to review Takeda's Actos-alogliptin combo

07/23/2009 | Bloomberg

Takeda Pharmaceutical said the FDA moved to Sept. 4 its deadline to decide whether to approve a drug that blends diabetes drugs Actos and alogliptin. Review of the fixed-dose combination is separate from Takeda's application for alogliptin, which failed to gain FDA approval last month.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC